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Objectives: The sensitivity of the current 10 mm cut-off diameter that is used to diagnose 23 
lymph node (LN) metastasis is too low. This is the first study to develop a new criterion to 24 
diagnose LN metastasis in a region-by-region manner using multi-detector computed 25 
tomography (MDCT). 26 
Methods: 1) The short-axis diameter of the LNs in MDCT images from 1-mm slices 27 
obtained immediately prior to surgery was compared with the pathological diagnosis in 78 28 
uterine cervical cancer patients undergoing primary surgery. For the region-by-region 29 
analysis, we divided para-aortic and pelvic spaces into 13 regions. 2) In 28 cases in which 30 
patients received neoadjuvant chemotherapy (NAC) followed by surgery, we compared 31 
MDCT images before and after NAC.  32 
Results: 1) The optimal cut-off in the region-by-region analysis was 5 mm, yielding 71% 33 
sensitivity and 79% specificity. 2) NAC significantly decreased LN size (p<0.0001). NAC 34 
decreased the number of swollen LN regions (>5 mm) from 51% (81/158) to 26% (41/158).  35 
Conclusions: The new criterion developed using MDCT could be effective for accurately 36 
assessing LN status. It also facilitates the assessment of NAC efficacy regarding the 37 




Cervical cancer is the second most common gynecologic malignancy in the world [1]. 41 
In addition to surgery and radiotherapy, neoadjuvant chemotherapy (NAC) followed by 42 
surgery has been used to treat locally advanced cervical cancer [2]. Because the prognosis of 43 
patients with cervical cancer depends largely on lymph node (LN) metastasis [3–5], it is 44 
important to assess the LN status accurately before starting treatment. 45 
Based on studies comparing the size of the LNs in images and pathological diagnoses, 46 
a 10 mm short-axis diameter became the currently accepted cut-off in both clinical practice 47 
and clinical trials [6–8]. However, the sensitivity of this conventional criterion has been 48 
reported to be as low as 25% [9]. Furthermore, previous studies have generally predicted the 49 
presence of LN metastases in the patient without describing the location. In the present study, 50 
we conducted a detailed, region-by-region analysis to generate a new criterion that could 51 
identify region-specific, swollen LNs. The use of our criterion could lead to the improvement 52 
of individualized treatments. 53 
In conducting the detailed analysis of LN status, the width of the slices, 7 mm in 54 
conventional CT and 5 mm in MRI, was considered to be a key limitation [7]. We therefore 55 
used a multi-detector CT (MDCT) scanner, which allowed one mm slice images [10, 11]. 56 
 5 
Using MDCT, we successfully generated a new criterion to diagnose LN metastasis. Using 57 
the new criterion, we were able to examine the efficacy of NAC in eradicating LN metastases 58 
in a region-by-region manner for the first time. 59 
60 
 6 
MATERIALS AND METHODS 61 
Assessment of MDCT images 62 
Patients 63 
Patients with stage IA2 to IIB cervical cancer who were being treated in our 64 
department were retrospectively analyzed. Staging was performed according to the 65 
Classification of International Federation of Gynecology and Obstetrics (FIGO, 1994) [12]. 66 
With the written consent of each patient, and under the approval of the ethics committee, we 67 
initiated the MDCT study in January 2007: 106 patients underwent MDCT examination 68 
within two weeks before surgery; 78 patients underwent primary surgery; and the remaining 69 
28 patients received NAC followed by surgery. In Table 1, we show the number of patients 70 
arranged according to their cancer stage.  71 
Lymphadenectomy was performed during all of the surgeries, and we resected LNs 72 
separately in a region-by-region manner and made pathological diagnoses for each sample. 73 
NAC regimen and indication 74 
Because squamous cell carcinoma (SCC) was more sensitive than adenocarcinoma to 75 
chemotherapy in our preliminary analysis, we administered NAC primarily in stage 76 




on days one and eight) and nedaplatin (NDP) (80 mg/m
2
 on day one) was administered. 78 
Cycles were repeated every 21 days. In total, we conducted two cycles of NAC.  79 
Surgical procedures and the definition of LN location 80 
Pelvic lymphadenectomy was conducted in association with type III radical 81 
hysterectomy. The surgical procedure has been reported previously [13].  82 
Para-aortic lymphadenectomy was performed when a metastatic pelvic LN was found 83 
after the intraoperative pathological diagnosis of frozen sections or when the surgeon found it 84 
necessary. LNs and their surrounding tissue were removed from the bifurcation of the 85 
common iliac artery to either the inferior mesenteric artery (IMA) or the level of the renal 86 
vein.  87 
MDCT protocol 88 
The MDCT examination was performed using one of three 64-detector-row CT 89 
scanners (Aquilion, Toshiba Medical Systems, Otawara, Japan) or a 16-detector-row CT 90 
scanner (Aquilion, Toshiba Medical Systems, Otawara, Japan). Patients were placed in the 91 
supine position, and the whole abdomen and pelvis were scanned. Image data were acquired 92 
with a 7 mm slice thickness, using a 64 × 0.5 mm (64-detector-row CT) or 16 × 1.0 mm 93 
(16-detector-row CT) beam collimation, a 500 msec rotation time, and a 120 kVp and 27.5 94 
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mm (64-detector-row CT) or 14.9 mm (16-detector-row CT) table feed per rotation. The 95 
acquired images were used to generate images with 1 mm slice thickness. All dual-phase 96 
contrast-enhanced CT images with a single breath-hold were obtained at 90 seconds 97 
following the intravenous injection of 100 ml of 300 or 350 mg/ml non-ionic contrast 98 
medium (IomeronⓇ350, Eisai, Tokyo, Japan; IopamironⓇ300, Bayer HealthCare, Osaka, 99 
Japan; or OmnipaqueⓇ300, Daiichi-Sankyo, Tokyo, Japan) at a rate of 2.5 ml/sec using an 100 
automatic injector. 101 
Because our MDCT procedure is the same as previously reported [14], the estimated 102 
radiation dose to the whole abdomen was approximately 10mSv. The noise of the images 103 
with 1mm thickness was greater than those with 7mm thickness. However, there was no 104 
difficulty in evaluating length of LNs, especially in MDCT images with contrast 105 
enhancement. 106 
Evaluation of LNs by MDCT 107 
The evaluation of LNs using the MDCT images of 1 mm-thick slices was performed 108 
independently by a radiologist (AK) who specializes in the field of gynecology and by a 109 
gynecologic oncologist (KY). The size of each LN, measured independently by AK and KY 110 
to the first decimal place, was determined by consensus of them.  111 
 9 
Region-by-region analysis 112 
Most previous studies have been conducted in patient-by-patient manner. In this 113 
study, we aimed to analyze more closely. Because it is unfeasible to compare each LN 114 
detected in MDCT images with LN detected in operation in node-by-node manner, we 115 
employed a region-by-region analysis. In a previous study, the pelvic and para-aortic spaces 116 
were divided into five regions prior to conducting a region-by-region analysis [9]. In the 117 
present study, we divided them into 13 regions (Supplementary Figure 1) to conduct a more 118 
detailed analysis. We determined the size of the largest LN in each region, termed the 119 
regional LN (Reg-LN), and compared it with the pathological diagnosis of LN metastasis in 120 
each region. We should note that even if LN metastasis existed in a region, the Reg-LN might 121 
not be the involved LN. Receiver operating characteristic (ROC) curve were drawn to 122 
determine the optimal cut-off size. For the development of the new criterion, we analyzed 123 
only the primary operation cases and excluded the NAC cases. 124 
Estimate of the efficacy of NAC in eradicating LN metastases using MDCT images 125 
In patients who received NAC, we performed the MDCT examination before and 126 
after NAC and compared the results. Using the new criterion for determining the swollen 127 
Reg-LN, we estimated the efficacy of NAC in eradicating LN metastasis. 128 
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 129 
Statistical methods 130 
We used t-tests to compare the parametric values between two groups and one-way 131 
ANOVA for three groups. Paired t-tests were used for the paired analysis. To analyze the 132 
distribution in a 2x2 table, Fisher’s exact test was employed. To analyze the distribution in a 133 





Detection of LNs in 1 mm slice images from MDCT. 138 
A total of 4,765 LNs were pathologically identified within 980 regions from 106 139 
patients, whereas the total number of visible LNs in the MDCT images was 800. Thus, the 140 
detection rate of LNs by MDCT was 17% (800/4,765). The most difficult LN to detect was 141 
the presacral LN (6%), whereas the easiest was the left common iliac LN (46%) (Figure 1a). 142 
Only seven of the 800 visible LNs in the MDCT images were over 10 mm in diameter.  143 
Among 980 regions from 106 patients, 563 (57%) regions showed one or more visible 144 
LNs in the MDCT images. Metastases were identified pathologically in 133 LNs within 80 145 
regions from 33 patients. Sixty of these 80 (75%) regions showed one or more visible LNs in 146 
the MDCT images (Figure 1b). The detection rate was significantly higher in the metastatic 147 
regions than in the non-metastatic regions (p=0.006) (Figure 1b). In the following analyses, 148 
the largest LN in each region was defined as the Reg-LN. 149 
Development of a new criterion to diagnose LN metastasis. 150 
We compared the size of the Reg-LN identified by MDCT with the presence or 151 
absence of a pathologically involved LN in 410 regions from 71 patients who underwent 152 
primary surgery and in whom the Reg-LN could be detected in the MDCT images. Statistical 153 
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analysis using the ROC curve is difficult when the number of metastasis-positive cases is less 154 
than five. Only the external iliac and obturator regions were positive for metastasis in five or 155 
more patients. Thus, we analyzed the Reg-LNs of the obturator region, external iliac region, 156 
and the other regions separately. In all three groups, the size of the Reg-LN was significantly 157 
larger in the LN regions containing metastases than in the non-metastatic regions; the mean 158 
was 7.9 in the metastatic case vs. 4.0 mm in the non-metastatic case in the external iliac 159 
(p<0.0001), 6.6 vs. 3.9 mm in the obturator (p<0.0001), and 5.1 vs. 3.8 mm in the other 160 
regions (p=0.003) (Figure 2a). The variation in the size of the Reg-LNs in these three groups 161 
was not significant in either metastatic or non-metastatic regions (Figure 2a). The optimal 162 
cut-off sizes determined by the ROC curves in the external iliac, obturator, and other regions 163 
were 4.9, 5.3, and 5.1 mm, respectively (Figure 2b). Based on these results, 5 mm was 164 
selected as the cut-off size for all types of LN regions.  165 
We then analyzed the Reg-LNs from all regions. The size of the Reg-LNs was 166 
significantly larger in the LN regions containing metastases than in the regions without 167 
metastases: mean 6.4 mm vs. 3.9 mm (p<0.0001) (Figure 3a). Based on the ROC curve, the 168 
optimal cut-off size to diagnose a LN metastasis was 4.7 mm (AUC = 0.80, Figure 3b). In the 169 
region-by-region analysis, we decided the closest whole number, 5 mm, as the cut-off for 170 
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clinical use. When the 5 mm cut-off was used, the sensitivity, specificity, positive predictive 171 
value (PPV), and negative predictive value were 70, 79, 27, and 96%, respectively.  172 
Next, we divided all cases into SCC and non-SCC to examine the influence of 173 
histological differences on the detection of LN metastasis. In both SCC and non-SCC patients, 174 
the size of the Reg-LN was significantly larger in the LN regions with metastases than in the 175 
non-metastatic regions: the mean in SCC was 7.1 vs. 4.0 mm and in non-SCC was 6.0 vs. 3.7 176 
mm (p<0.0001) (Figure 3a). The size of the Reg-LN in non-metastatic LN regions was larger 177 
in SCC compared with non-SCC, but the difference was small (Figure 3a). The optimal 178 
cut-off determined by the ROC curve was 5.4 mm in SCC and 4.7 mm in non-SCC cases 179 
(Figure 3c). Thus, 5 mm, the closest whole number, was again selected for use in both 180 
histological subtypes. 181 
We also evaluated the conventional 10 mm cut-off. In the primary surgery cases, only 182 
four of all the visible LNs in the MDCT images were over 10 mm in diameter (Figure 2a). 183 
We found that the conventional cut-off of 10 mm was far from the optimal cut-off based on 184 
the ROC analyses (Figure 2b, 3b, 3c). In addition, we randomly divided our data (primary 185 
surgery cases, region-by-region data) into three groups and conducted ROC analyses 186 
independently, thus generating cut-off values of 4.9, 5.0 and 5.3 (95% CI; 4.55-5.58, data not 187 
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shown). We therefore concluded that the conventional 10 mm cut-off is statistically 188 
inappropriate in MDCT images. 189 
Assessment of NAC efficacy on metastatic LNs in cervical cancer. 190 
We analyzed 153 Reg-LNs from 28 patients who underwent NAC followed by 191 
surgery using the MDCT images taken just before surgery. As in the primary surgery cases, 192 
the size of the Reg-LN was significantly larger in the metastatic regions than in the 193 
non-metastatic regions: the mean was 7.4 vs. 3.9 mm (p<0.0001) (Figure 4a). The size of the 194 
Reg-LN in the metastatic and non-metastatic LN regions was the same within the NAC and 195 
primary surgery groups (Figure 4a). Similar to the primary surgery cases (Figure 4b), the 196 
optimal cut-off determined by the ROC curve was 4.7 mm in NAC cases (AUC = 0.83, 197 
Figure 4c). 198 
Next, we examined the size change of LNs after NAC. For this analysis, 199 
node-by-node comparison was performed. First, we compared the size of all visible 328 LNs 200 
individually between before and after NAC. NAC significantly decreased the size of LNs 201 
from 5.1 to 3.5 mm (p<0.0001) (Figure 5a): this is the reduction in the average size of all 202 
visible LNs. For Reg-LNs, we found 158 Reg-LNs in MDCT images before NAC. The size 203 
of these 158 Reg-LNs was also significantly decreased by NAC from 5.9 to 4.3 mm 204 
 15 
(p<0.0001) (Figure 5b). Using the cut-off of 5 mm, 80 out of 158 Reg-LNs (51%) were 5 mm 205 
or greater in diameter before NAC. After NAC, the number of Reg-LNs that were 5 mm or 206 
greater was significantly decreased to 41 (p<0.0001, 26%) (Figure 5c). Of these 41 regions, 207 
13 (32%) had LN metastases based on their pathology. Among 78 regions that were less than 208 
5 mm in diameter before NAC, a LN metastasis was identified in only 1 region (1%) after 209 
NAC. 210 
In addition to the analysis of MDCT images, we reviewed the medical records of 211 
cervical cancer cases that were treated in our hospital between 1999 and 2011. In accordance 212 
with the MDCT analysis, we found that NAC decreased the frequency of LN metastasis 213 




The main objective of this study was to generate a new and more reliable criterion to 217 
diagnose LN metastasis pre-operatively. We also evaluated the efficacy of NAC in 218 
eradicating LN metastasis using the newly developed criterion because NAC has the potential 219 
to eradicate LN and distant metastases [2, 15, 16].  220 
CT and MRI have been widely used to diagnose LN metastasis [17, 18]. In 221 
conventional CT or MRI images of 5-7 mm slices, 10 mm is used as the conventional cut-off 222 
for the short-axis diameter in the diagnosis of swollen LNs as potential metastases. However, 223 
only seven of 800 visible LNs in the MDCT images were over 10 mm in diameter in this 224 
study (data not shown). Therefore, the conventional cut-off of 10 mm is not effective in 225 
clinical practice. The conventional cut-off is used because of the limitations of conventional 226 
CT, which cannot reproducibly measure an object smaller than 10 mm in diameter in 5-7 mm 227 
slices [7]. 228 
MDCT is a new form of CT technology and that has an increased speed of CT image 229 
acquisition [18]. In addition, MDCT provides more information than CT without increasing 230 
cost, examination time, or exposure dose depending on how it is protocoled. Although there 231 
are reports demonstrating the use of MDCT to diagnose LN metastasis in gastric, 232 
 17 
oesophageal, breast and pancreatic cancer [10, 11, 20-22], to the best of our knowledge, this 233 
is the first report on the use of MDCT in a gynecological cancer. 234 
In previous studies that examined the diagnostic rate for LN metastasis, 235 
patient-by-patient analysis was used to compare the size of the largest LN in a patient with 236 
the pathological diagnosis of the LN metastasis, without describing the location of LN 237 
metastasis. However, to consider individually the extent of the lymphadenectomy and field of 238 
radiotherapy, a diagnosis of not only the presence of a LN metastasis but also the location(s) 239 
of the LN metastasis is essential. Accordingly, we determined that the cut-off should be 240 
ascertained using region-by-region analysis.  241 
Our findings suggested that 5 mm was the most appropriate cut-off for clinical 242 
practice. In addition, a cut-off of 5 mm using MDCT was reproducible regardless of the 243 
location or pathological subtype of the tumor (Figures 3b, 3c, 4c). The ROC analyses clearly 244 
showed that a cut-off of 10mm is not appropriate.  245 
Using historical analysis of stage IB2/IIA cases, we found that the frequency of LN 246 
metastasis in NAC cases was significantly lower than in primary surgery cases 247 
(Supplementary Figure 2b). This result is consistent with previous reports that the frequency 248 
of LN metastasis is lower in patients who undergo NAC [15, 16]. In our analysis, 249 
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approximately half of the Reg-LNs that were 5 mm or larger shrank to less than 5 mm after 250 
NAC (Figure 5c). Although shrinkage of LNs does not necessary mean anti-tumor effect 251 
against involved LNs, this study shows a substantial number of involved LNs might have 252 
been cured by NAC. Ours is the first study to report the precise change in LN size due to 253 
NAC; however, further studies are required to confirm whether NAC is effective against the 254 
LN metastasis of cervical cancer. 255 
In this study, using 1mm slice images, we tried evaluating LN size as closely as 256 
possible in region-by-region manner, but there are still some limitations. The largest LN in an 257 
involved region may not always be the involved LN. To compare the preoperative image with 258 
the pathological diagnosis in node-by-node manner, data accumulated from image-guided 259 
surgery, currently used for gastric or liver cancer [23, 24] are necessary. Although the 260 
detection rate of at least one LN in a region was increased when involved LNs exist, the 261 
detection rate was still 75 %, not 100% (Figure 1b). Among operable cervical caner patients, 262 
PPV of 5 mm cut-off was only 27% although PPV is thought to be higher in advanced cases 263 
where operation is impossible and radiotherapy is indicated.  264 
Regardless, the results of our study should have an enormous impact on clinical 265 
practice. We consider LNs of 5 mm or larger to be potentially metastatic. We hope this result 266 
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would be validated in a prospective study with a large number of cases and node-by-node 267 
surgery with imaging analysis. 268 
In conclusion, we suggested an optimal cut-off of 5 mm in MDCT images for the 269 
diagnosis of metastatic LNs within an LN region. This novel diagnostic criterion would 270 
improve the individualized treatment of cervical cancer patients. In the future, clinical trials 271 
should be performed to investigate whether this strategy could improve the prognosis of 272 
cervical cancer patients. 273 
 274 
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FIGURE LEGENDS 348 
Figure 1. Detection of LNs in MDCT images. a) The number of detected LNs by MDCT is 349 
indicated by a black box. Pathologically detected LNs are indicated by the sum of the 350 
detected and undetected LNs. The distribution was statistically significant (p<0.0001, 351 
chi-square test). PAN: para-aortic LN region; IMA: inferior mesenteric artery; Bif: aortic 352 
bifurcation; L: left; R: right. b) The detection rate of Reg-LNs was significantly higher in the 353 
involved regions (pN1) than in the uninvolved regions (pN0) (p=0.006). 354 
Figure 2. Region-by-region analysis of LNs. a) Each dot indicates the size of the Reg-LN. 355 
Red dots indicate size of involved Reg-LNs and tiny black dots indicate size of uninvolved 356 
Reg-LNs. Black bar indicates the mean size. Ext: external iliac region; Obt: obturator region; 357 
Others: all other regions. One-way ANOVA was used for the statistical analysis. b) ROC 358 
curves based on the size of the Reg-LN and the presence of the LN metastasis. The gray 359 
arrowhead indicates the optimal cut-off based on the ROC curves. Note that the 10mm 360 
cut-off indicated by the black arrowhead is away from the optimal cut-off based on the ROC 361 
analysis. 362 
Figure 3. Region-by-region analysis of all Reg-LNs among different histological subtypes. a) 363 
Each dot indicates the size of the Reg-LN. Red dots indicate size of involved Reg-LNs and 364 
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tiny black dots indicate size of uninvolved Reg-LNs. Black bar indicates the mean size. To 365 
detect the association of all Reg-LNs with the different histological subtypes present in the 366 
three groups, one-way ANOVA was performed. b) ROC curves are based on the size of the 367 
Reg-LN and the presence of the LN metastases. c) ROC curve analyses were conducted by 368 
dividing the cases into different histological subtypes. The gray arrowhead indicates the 369 
optimal cut-off based on the ROC curves. Note that the 10mm cut-off indicated by the black 370 
arrowhead is away from the optimal cut-off based on the ROC analysis. 371 
Figure 4. Region-by-region analysis for primary surgery cases and NAC cases, and the effect 372 
of NAC based on the analysis of MDCT images. a) Each dot indicates the size of the Reg-LN. 373 
Primary: primary surgery; pN0: no LN metastasis; pN1: LN metastasis; NS: not statistically 374 
significant. b) ROC curves are based on the size of the Reg-LN and the presence of the LN 375 
metastasis in all primary surgery cases. The gray arrowhead indicates the optimal cut-off 376 
based on the ROC curves. c) ROC curve representing only the NAC cases. The cut-off in the 377 
NAC cases was 4.7 mm.  378 
Figure 5. Effect of NAC according to MDCT images. a) Changes in all LN sizes that were 379 
visible before NAC. They shrank significantly after NAC (p<0.0001). b) Changes in all 380 
Reg-LN sizes by NAC. They also shrank significantly (p<0.0001). c) NAC’s effect of 381 
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decreasing the proportion of regions with a LN larger than 5 mm (black bar). Red boxes 382 
indicate regions with LN metastasis. NAC decreased the number of regions with LNs larger 383 
than 5 mm from 80 to 41. In the 41 regions that had Reg-LNs larger than 5mm after NAC, we 384 
found 13 (32%) involved regions; in the 117 regions that had Reg-LNs smaller than 5 mm 385 
after NAC, we found 6 (5%) involved regions. 386 
Supplementary Figure 1. We divided para-aortic and pelvic lymph nodes into 13 regions to 387 
compare pre-operative images with the pathological diagnosis. a) para-aortic lymph nodes, 388 
from IMA to renal vein; b) para-aortic lymph nodes, from bifurcation to IMA; c) right 389 
common iliac lymph nodes; d) left common iliac lymph nodes; e) presacral lymph nodes; f) 390 
right external iliac lymph nodes; g) right internal iliac lymph nodes; h) left internal iliac 391 
lymph nodes; i) left external iliac lymph nodes; j) right superficial inguinal lymph nodes; k) 392 
lymph nodes in the right obturator fossa (obturator, carinal, uterine artery, and deep inguinal 393 
lymph nodes); l) lymph nodes in the left obturator fossa; m) left superficial inguinal lymph 394 
nodes.  395 
Supplementary Figure 2. a) Changes in the treatment modality for SCC cases in our 396 
hospital. For stage IB2/IIA SCC cases, we predominantly performed the primary operation 397 
before 2006 and the NAC after 2007. b) NAC decreased the frequency of LN metastasis in 398 
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stage IB2/IIA SCC patients. c) Among IB2/IIA cases, NAC-treated cases showed a tendency 399 
toward better survival compared with the primary operation cases, although this result was 400 





Table 1. Number of patients multi-detector CT image was analyzed.  405 
 406 
Stage SCC Non-SCC Total 
IA 4 3 7 
IB1 32 20 52 
IB2 10 (7) 4 (1) 14 (8) 
IIA 4 1 5 
IIB 23 (19) 5 (1) 28 (20) 
Total 73 (26) 33 (2) 106 (28) 













Historical analysis of the effect of NAC in eradicating LN metastases 
MATERIALS AND METHODS 
Patients 
With the written consent of each patient and the approval of our ethics 
committee, we retrospectively reviewed the medical records of 296 cervical cancer 
cases (stage IA, IB, and IIB) who underwent systematic lymphadenectomy at our 
department between 1999 and 2011. The median number of resected pelvic lymph 
nodes was 44±38 (mean±2SD) per patient. A total of 199 were diagnosed with SCC and 
97 with non-SCC (adenocarcinoma, adenosquamous carcinoma, etc.) (Supplementary 
Table 1). 
 
NAC regimen and indication 
NAC regimens are shown in Supplementary table 2. Between 1999 and 2006, 
the most frequently used regimen was transarterial infusion of cisplatin (CDDP), (100 
mg/m
2
), pirarubicin (THP), (25 mg/m
2
), and mitomycin-C (MMC), (20 mg/patient) 
every 28 days. Between 2007 and 2011, intravenous infusion of irinotecan (CPT-11), 
(60 mg/m
2
 on days 1 and 8) and nedaplatin (NDP), (80 mg/m
2
 on day 1) every 21 days 
was most frequently used. In principle, we conducted 2 cycles of NAC. 
Because squamous cell carcinoma (SCC) was more sensitive than 
adenocarcinoma to chemotherapy in our preliminary analysis, we administered NAC 
primarily in SCC cases. As a result, most NAC cases (57/63) were SCC. From 1999 to 
2011, for most stage IIB SCC patients, we administered NAC before operation. For 
stage IB2/IIA SCC patients, until 2006, we administered NAC for only those who had 
very bulky tumours, and most cases underwent primary operation. In 2007, we changed 
our policy and have therefore administered NAC for most IB2/IIA SCC cases. As a 
result, the proportion of stage IB2/IIA patients who received NAC increased 
significantly from 4/29 (14% through 2006) to 10/17 (59%, 2007 onward) 
(supplementary Figure 2a). Therefore, the primary operation and NAC were comparable 
among IB2/IIA cases. 
 
Statistical methods 
To analyse the distribution in a 2x2 table, Fisher’s exact test was employed. To 
analyse the distribution in a larger table, the chi-square test was used. We considered 
p<0.05 a significant difference. 
 
RESULTS 
Of 296 patients receiving lymphadenectomy from 1999 to 2011, 63 received 
NAC. Response rate (complete response or partial response) of NAC was 91% (52/57). 
Because we changed our treatment policy for stage IB2/IIA SCC cases in 2007, we 
compared the rate of pathologically positive LN metastases in stage IB2/IIA SCC cases 
between the period of 1999-2006 and the period of 2007-2011. The rate of LN 
metastasis decreased from 41% (12/29, through 2006) to 24% (4/17, 2007 onward), 
although this difference was not statistically significant. Dividing all IB2/IIA SCC cases 
into NAC and primary surgery groups, the LN metastasis rate was significantly lower in 
NAC than in the primary surgery group (1/14, 7% vs 15/32, 47%) (p=0.02) 
(Supplementary Figure 2b). The overall survival rate of IB2/IIA SCC patients who 




Supplementary Table 1: Number of patients receiving lymphadenectomy from 1999 to 
2011. 
Stage SCC Non-SCC Total 
IA 14 7 21 
IB1 87 56(1) 141(1) 
IB2 28(11) 18(1) 46(12) 
IIA 16(2) 4(1) 20(3) 
IIB 54(43) 12(4) 66(47) 
Total 199(56) 97(7) 296 (63) 
( ); NAC cases. 
 
Supplementary Table 2: NAC regimen. Numbers of patients are shown in the table. 
  stage IB2 stage IIA stage IIB Total 
CPT-11/NDP 9 0 22 31 
CDDP/THP/MMC * 2 2 15 19 
NDP/Peplomycin/Ifomide 1 1 4 6 
CPT-11/CDDP 1 0 1 2 
Taxol/Carboplatin 0 0 4 4 
Docetaxel/Carboplatin 0 0 1 1 
*Transarterial infusion. 
 
 
  
 
  
 
